DexCom Management
Management criteria checks 3/4
DexCom's CEO is Jake Leach, appointed in May 2025, has a tenure of 1.17 years. total yearly compensation is $7.99M, comprised of 9.6% salary and 90.4% bonuses, including company stock and options. directly owns 0.083% of the company’s shares, worth $22.94M. The average tenure of the management team and the board of directors is 4.9 years and 6.3 years respectively.
Key information
Jake Leach
Chief executive officer
US$8.0m
Total compensation
| CEO salary percentage | 9.63% |
| CEO tenure | 1.2yrs |
| CEO ownership | 0.08% |
| Management average tenure | 4.9yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Seeking Alpha • Jul 02
DexCom: The Growth Thesis Still Needs To Be Proven
Summary DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes market. DXCM aims to expand CGM adoption to Type 2 non-insulin patients, but commercial uptake remains unproven despite positive clinical trial results. At 28x earnings, DXCM's valuation is not demanding, yet offers limited upside given execution risks and the need for evidence of new market penetration. I assign DXCM a Hold rating, pending clearer signs that expansion into non-insulin patients drives sustainable growth. Read the full article on Seeking Alpha
Narrative Update • Jun 26
DXCM: Future CGM Adoption And Trial Data Will Test Premium Expectations
DexCom's analyst fair value estimate has been revised higher to about $67.93. Analysts point to stronger expectations around continuous glucose monitor adoption, positive CONNECT data, and easing concerns following investor day updates as key drivers behind a higher assumed revenue growth rate and a premium future P/E multiple, partly offset by a lower profit margin outlook.Analysis Article • Jun 20
DexCom (DXCM) Stock Could Be 13.1% Undervalued After Pediatric Stelo Clearance
DexCom (DXCM) is back in focus after US regulators cleared its Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children who do not use insulin, expanding its reach in the pediatric market. See our latest analysis for DexCom. At a share price of US$72.47, DexCom’s recent 90-day share price return of 8.24% contrasts with a 1-year total shareholder return that declined 9.41%. This suggests recent momentum has picked up after a weaker period, as...
Narrative Update • Jun 09
DXCM: CONNECT Data And Digital Health Expansion Will Shape Balanced Future Outlook
DexCom's analyst price target has moved slightly higher to $83.42 from $81.64, as analysts factor in updated survey work and clinical data that they view as supportive of continuous glucose monitor adoption, particularly in the Type 2 non insulin segment. Analyst Commentary Recent Street research on DexCom reflects a mix of optimism around continuous glucose monitor adoption, especially for Type 2 non insulin users, and more restrained views on valuation and long term targets.Narrative Update • May 26
DXCM: New Long Term Framework And Buybacks Will Support Future Momentum
Analysts have nudged their average price target for DexCom slightly lower to about $82, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and a P/E multiple that are broadly consistent with recent cuts in Street targets to $64 to $82, as firms factor in lower peer multiples and management's new long term guidance. Analyst Commentary Recent research on DexCom clusters around a tighter valuation range, with most firms updating price targets and assumptions after the latest investor and analyst events.Narrative Update • May 07
DXCM: Share Repurchases And Guidance Reaffirmation Will Support Future Healthcare Momentum
Analysts have trimmed their average price target on DexCom by about $3 to reflect slightly lower modeled revenue growth, a modestly reduced future P/E assumption, and updates to discount rate and margin expectations following a series of recent target changes across Wall Street firms. Analyst Commentary Recent research on DexCom has centered on fine tuning price targets and valuation assumptions rather than making wholesale changes to fundamental views.New Narrative • May 02
Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook
Catalysts About DexCom DexCom develops and sells continuous glucose monitoring systems used by people with diabetes around the world. What are the underlying business or industry changes driving this perspective?Narrative Update • Apr 22
DXCM: AI Coaching And Share Repurchases Will Support Future Healthcare Momentum
Analysts have made a small trim to DexCom's implied value, cutting the analyst price target by about $0.25, as they balance slightly softer modeled growth and margins with generally supportive recent research, including multiple target increases following the latest medtech sector updates. Analyst Commentary Recent research on DexCom reflects a mix of optimism and caution as analysts adjust their models and targets across the medtech group.Narrative Update • Apr 05
DXCM: AI Coaching And Buybacks Will Support Future Healthcare Momentum
Analysts have nudged DexCom's fair value estimate higher to $87.13 from $86.12, citing a series of upward price target revisions that cluster around the low to mid $80s, while one firm maintains a more cautious view focused on rising competition. Analyst Commentary Recent research on DexCom reflects a split view, with several bullish analysts lifting price targets into the low to mid US$80s, while at least one bearish voice is positioning closer to the low US$70s.Narrative Update • Mar 22
DXCM: AI Coaching And Buybacks Will Support Future Market Share Confidence
DexCom's fair value estimate edges up by about $0.27 as analysts fine tune assumptions on the discount rate, revenue growth, profit margin, and future P/E, following a mix of price target changes across the Street, including recent upward revisions toward $84 to $86 and a lower $71 target tied to competition concerns. Analyst Commentary Recent Street research on DexCom reflects a split view, with some firms nudging targets higher into the mid $80s and others pushing back toward the low $70s on competition concerns.Narrative Update • Mar 08
DXCM: AI Coaching And Share Repurchases Will Support Long-Term Confidence
DexCom's intrinsic value estimate nudged higher to $85.85, with analysts modestly lifting price targets, often in the $1 to $12 range, as they weigh recent target increases against a Barclays downgrade that highlights rising competitive pressure in continuous glucose monitoring. Analyst Commentary Recent research on DexCom reflects a split tape, with several firms adjusting price targets higher by amounts in the low single digits to low teens, while one major firm has moved to a more cautious stance with a lower target and an Underweight rating.Narrative Update • Feb 21
DXCM: Medicare Support And AI Coaching Rollout Will Sustain Long-Term Confidence
Our updated DexCom narrative reflects a small increase in fair value to $85.46. Analysts point to a mix of modestly lower assumed revenue growth, slightly higher profit margin expectations, a reduced future P/E multiple, and a series of recent price target adjustments that are mostly higher in dollar terms despite some concerns around rising competition.Analysis Article • Feb 19
The Strong Earnings Posted By DexCom (NASDAQ:DXCM) Are A Good Indication Of The Strength Of The Business
Even though DexCom, Inc.'s ( NASDAQ:DXCM ) recent earnings release was robust, the market didn't seem to notice. Our...Narrative Update • Feb 05
DXCM: Medicare Support And AI Coaching Features Will Sustain Long-Term Confidence
Analysts made only a slight upward tweak to the DexCom price target to about US$85, reflecting small adjustments to their growth, margin and P/E assumptions as they balance caution on rising competition with support from recent positive research updates. Analyst Commentary Recent research on DexCom reflects a split view, with some analysts highlighting supportive policy signals and valuation upside, while others focus on intensifying competition and reduced price targets.Narrative Update • Jan 22
DXCM: Medicare Support And 2026 Sensor Expansion Will Sustain Long-Term Confidence
Our DexCom price target edges down to about $85 from $85.27, reflecting slightly lower assumed profit margins and P/E multiple, partly offset by analysts citing supportive Medicare reimbursement commentary and mixed Street views on competition, valuation, and 2026 guidance. Analyst Commentary Recent research on DexCom highlights a clear split between bullish and bearish analysts, with views clustering around competition, execution on guidance, and how much investors are willing to pay for the stock through the P/E multiple.Narrative Update • Jan 07
DXCM: Medicare Support And New Sensor Duration Will Sustain Long-Term Confidence
Analysts nudged their fair value estimate for DexCom slightly higher to about $85 per share, citing a generally supportive regulatory backdrop for continuous glucose monitors and noting that recent price target cuts still reflect confidence in the company’s long term patient growth and product profile. Analyst Commentary Recent research updates on DexCom highlight a mix of optimism around the core continuous glucose monitor franchise and caution around guidance, pricing, and execution into 2026.Narrative Update • Dec 15
DXCM: Medicare Reimbursement Stability Will Support Confidence Despite Emerging Legal And Safety Headlines
Analysts have nudged our DexCom fair value estimate slightly higher, from $84.31 to $84.85, as they balance recent price target cuts with continued Buy and Outperform ratings that point to resilient growth, stable margins, and a favorable regulatory and product backdrop. Analyst Commentary Street research continues to reflect a constructive long term view on DexCom, even as recent reports incorporate more conservative assumptions and lower base case price targets.Narrative Update • Nov 29
DXCM: Medicare Payment Developments Will Drive Confidence Despite Recent Short-Term Weakness
DexCom's analyst price target has decreased modestly to approximately $84.31 from $84.96, as analysts cite a mix of positive Medicare policy developments and tempered optimism following company guidance updates and recent survey data. Analyst Commentary Recent analyst research on DexCom reflects both optimism about the company's long-term prospects and concerns regarding near-term execution and growth trends.Narrative Update • Nov 15
DXCM: Share Recovery Likely With Positive Setup Expected For 2026
Analysts have lowered their price targets for DexCom, reducing the fair value estimate from $98.40 to $84.96. This reflects a reaction to recent conservative guidance, weaker growth outlook, and updated margin expectations.Analysis Article • Nov 02
Earnings Beat: DexCom, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
As you might know, DexCom, Inc. ( NASDAQ:DXCM ) just kicked off its latest quarterly results with some very strong...Narrative Update • Oct 31
DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty
The consensus analyst price target for DexCom was recently lowered, with the average fair value estimate moving down by less than $1 to approximately $98.40. Analysts cite investor concerns around the company’s conservative guidance and gross margin pressure, but remain generally positive on long-term growth and patient retention trends.Narrative Update • Oct 17
Insurance Reimbursement And Digital Health Integration Will Unlock Global Potential
DexCom's average analyst price target has decreased by approximately $1.58 to around $98.96. Analysts are recalibrating their outlook in light of mixed survey results and a shift in assumptions around reimbursement trends and profitability expectations.Narrative Update • Oct 03
Insurance Reimbursement And Digital Health Integration Will Unlock Global Potential
Analysts have modestly reduced DexCom's fair value estimate by approximately $1.54 to $100.54 per share. This change reflects slightly lower revenue growth projections and recent adjustments in price targets based on mixed survey data and evolving reimbursement trends.Analysis Article • Jul 22
We Think DexCom (NASDAQ:DXCM) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Jul 09
DexCom's (NASDAQ:DXCM) Returns On Capital Are Heading Higher
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Seeking Alpha • Mar 04
DexCom: Valuation Does Not Factor In Slowing Growth
Summary DexCom's growth is slowing, with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% growth. Intensifying competition from Abbott and Medtronic and the rise of GLP-1 drugs pose significant threats to DXCM's market position and growth projections. The valuation of DXCM at 43x non-GAAP forward P/E and 7.5x forward price to sales does not adequately factor in these emerging risks. Given the current competitive landscape and potential market disruptions, I recommend a sell rating on DXCM to lock in gains. Read the full article on Seeking AlphaSeeking Alpha • Jan 17
DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback
Summary DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, with muted enthusiasm from Wall Street today, and a "Hold" rating for me for 2025. I suspect the market overestimated DexCom's mass-market potential, leading to a reality check and a savage bear run on its stock in the past year. Future growth hinges on expanding into new markets and developing diverse products, but significant breakthroughs are likely years away. This is a great product for a specific market, not a mass-market. Read the full article on Seeking AlphaSeeking Alpha • Dec 10
DexCom: Brighter 2025 From Stelo Ramp
Summary DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors remains strong. Q3 revenue grew only 2% y/y to $994.2 million, with temporary and long-lasting headwinds impacting growth and margins. The new over-the-counter Stelo CGM launched in August, offering a new growth vector and targeting non-insulin users, with significant ramp-up expected in 2025. Despite current difficulties, improved execution and a successful Stelo ramp-up in 2025 are crucial for DexCom to regain its growth trajectory. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$930m |
| Dec 31 2025 | US$8m | US$769k | US$836m |
| Sep 30 2025 | n/a | n/a | US$721m |
| Jun 30 2025 | n/a | n/a | US$572m |
| Mar 31 2025 | n/a | n/a | US$535m |
| Dec 31 2024 | US$6m | US$682k | US$576m |
| Sep 30 2024 | n/a | n/a | US$681m |
| Jun 30 2024 | n/a | n/a | US$667m |
| Mar 31 2024 | n/a | n/a | US$639m |
| Dec 31 2023 | US$5m | US$625k | US$542m |
| Sep 30 2023 | n/a | n/a | US$377m |
| Jun 30 2023 | n/a | n/a | US$358m |
| Mar 31 2023 | n/a | n/a | US$293m |
| Dec 31 2022 | US$4m | US$535k | US$341m |
| Sep 30 2022 | n/a | n/a | US$244m |
| Jun 30 2022 | n/a | n/a | US$230m |
| Mar 31 2022 | n/a | n/a | US$258m |
| Dec 31 2021 | US$6m | US$450k | US$217m |
| Sep 30 2021 | n/a | n/a | US$577m |
| Jun 30 2021 | n/a | n/a | US$562m |
| Mar 31 2021 | n/a | n/a | US$530m |
| Dec 31 2020 | US$4m | US$409k | US$550m |
Compensation vs Market: Jake's total compensation ($USD7.99M) is below average for companies of similar size in the US market ($USD14.46M).
Compensation vs Earnings: Jake's compensation has increased by more than 20% in the past year.
CEO
Jake Leach (48 yo)
1.2yrs
Tenure
US$7,985,960
Compensation
Mr. Jacob Steven Leach, also known as Jake, served as Chief Operating Officer of DexCom, Inc from August 2022 until January 1, 2026 and serves as its President since May 2025 and serves as its Chief Execut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 18.7yrs | US$16.28m | 0.071% $ 19.6m | |
| President | 1.2yrs | US$7.99m | 0.083% $ 22.9m | |
| Executive VP | 6.3yrs | US$7.08m | 0.016% $ 4.4m | |
| Executive VP | 4.5yrs | US$6.34m | 0.0082% $ 2.3m | |
| Executive VP | 5.8yrs | US$6.25m | 0.014% $ 3.9m | |
| Executive VP & Chief Commercial Officer | 1.3yrs | US$6.84m | no data | |
| Executive VP & CTO | less than a year | no data | no data | |
| Vice President of Finance and Investor Relations | no data | no data | no data | |
| Executive Vice President of Strategy & Corporate Development | 5.3yrs | no data | 0.00051% $ 140.2k | |
| Executive Vice President of Global Business Services | 9.5yrs | US$2.92m | no data | |
| Senior Director of Global Medical Science & Education | no data | no data | no data | |
| Director of Medical Science & Education | no data | no data | no data |
4.9yrs
Average Tenure
53.5yo
Average Age
Experienced Management: DXCM's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 18.7yrs | US$16.28m | 0.071% $ 19.6m | |
| President | less than a year | US$7.99m | 0.083% $ 22.9m | |
| Lead Independent Director | 11.7yrs | US$489.08k | 0.014% $ 3.8m | |
| Independent Director | 12.7yrs | US$429.86k | 0.017% $ 4.5m | |
| Independent Director | 16.7yrs | US$430.63k | 0.010% $ 2.7m | |
| Independent Director | 6.8yrs | US$430.63k | 0.0065% $ 1.8m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 5.8yrs | US$443.09k | 0.0059% $ 1.6m | |
| Independent Director | less than a year | US$503.99k | no data | |
| Independent Director | 1.3yrs | US$553.88k | 0.00080% $ 219.9k | |
| Independent Director | 9.3yrs | US$433.02k | 0.010% $ 2.9m | |
| Independent Director | 2.9yrs | US$433.02k | 0.0027% $ 739.6k |
6.3yrs
Average Tenure
61.5yo
Average Age
Experienced Board: DXCM's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/05 20:11 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DexCom, Inc. is covered by 51 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Travis Steed | Barclays |
| Matthew Miksic | Barclays |